GlassScriptPhysician profile
Susama Verma
NPI 1285714097
$1,314.37
in general payments reported to CMS, 2019-2025
25 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2022: $78.75 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $212.83 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $175.52 | 2019 | |
| Amgen INC. | $112.20 | 2025 | Uplizna |
| Argenx US, INC. | $98.46 | 2022-2025 | Vyvgart Hytrulo |
| Abbvie INC. | $85.86 | 2025 | |
| Pfizer INC. | $77.91 | 2025 | |
| Biogen, INC. | $53.98 | 2025 | Vumerity, Skyclarys |
| Novartis Pharmaceuticals Corporation | $51.80 | 2025 | |
| Janssen Biotech, INC. | $46.03 | 2025 | |
| Neurelis, INC. | $45.69 | 2025 | Valtoco |
| Ucb, INC. | $40.38 | 2025 | Fintepla, Rystiggo |
| Mallinckrodt Hospital Products INC. | $39.88 | 2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $39.82 | 2025 | Hyqvia |
| Sk Life Science, INC. | $25.50 | 2025 | |
| Neurocrine Biosciences, INC. | $23.16 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.90 | 2025 | Infinity |
| Amneal Pharmaceuticals LLC | $21.71 | 2025 | Crexont |
| Livanova USA, INC. | $20.98 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Grifols USA, LLC | $20.51 | 2025 | Gamunex-C |
| Lilly USA, LLC | $19.71 | 2025 | Kisunla |
| Vanda Pharmaceuticals INC. | $18.21 | 2025 | Ponvory |
| Celgene Corporation | $16.16 | 2025 | Zeposia |
| Genentech USA, INC. | $15.65 | 2025 | Ocrevus Zunovo |
| Lundbeck LLC | $15.05 | 2025 | Vyepti |
| Cycle Pharmaceuticals INC | $14.47 | 2025 | Tascenso Odt, Bafiertam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susama Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.